ReferenceID 1762
Liquiritigenin suppresses the activation of hepatic stellate cells via targeting miR-181b/PTEN axis
Phytomedicine
BACKGROUND: Liquiritigenin (LQ), an aglycone of liquiritin in licorice, has demonstrated antioxidant, anti-inflammatory and anti-tumor activities. Previously, LQ was found to inhibit liver fibrosis progression. PURPOSE:
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 1762
- Evidence Id
- 18352
- Core Evidence Id
- 18352
- Source Reference Id
- 3497
- Herb2 Reference Id
- HBREF004294
- Subject Paper Key
- HBIN023519_31790896
- Pubmed Id
- 31790896
- Doi
- 10.1016/j.phymed.2019.153108
- Paper Title
- Liquiritigenin suppresses the activation of hepatic stellate cells via targeting miR-181b/PTEN axis
- Paper Abstract
- BACKGROUND: Liquiritigenin (LQ), an aglycone of liquiritin in licorice, has demonstrated antioxidant, anti-inflammatory and anti-tumor activities. Previously, LQ was found to inhibit liver fibrosis progression. PURPOSE: Phosphatase and tensin homolog (PTEN) has been reported to act as a negative regulator of hepatic stellate cell (HSC) activation. However, the roles of PTEN in the effects of LQ on liver fibrosis have not been identified to date. METHODS: The effects of LQ on liver fibrosis in carbon tetrachloride (CCl4) mice as well as primary HSCs were examined. Moreover, the roles of PTEN and microRNA-181b (miR-181b) in the effects of LQ on liver fibrosis were examined. RESULTS: LQ markedly ameliorated CCl4-induced liver fibrosis, with a reduction in collagen deposition as well as alpha-SMA level. Moreover, LQ induced an increase in PTEN and effectively inhibited HSC activation including cell proliferation, alpha-SMA and collagen expression, which was similar with curcumin (a positive control). Notably, loss of PTEN blocked down the effects of LQ on HSC activation. PTEN was confirmed as a target of miR-181b and miR-181b-mediated PTEN was involved in the effects of LQ on liver fibrosis. LQ led to a significant reduction in miR-181b expression. LQ-inhibited HSC activation could be restored by over-expression of miR-181b. Further studies demonstrated that LQ down-regulated miR-181b level via Sp1. Collectively, we demonstrate that LQ inhibits liver fibrosis, at least in part, via regulation of miR-181b and PTEN. CONCLUSION: LQ down-regulates miR-181b level, leading to the restoration of PTEN expression, which contributes to the suppression of HSC activation. LQ may be a potential candidate drug against liver fibrosis.
- Journal
- Phytomedicine
- Publish Year
- 2020
- Experiment Subject
- mouse
- Experiment Type
- Cell Experiment
- Phenotype Related
- Liver Fibrosis
- Paper Title Cn
- Paper Title En
- Liquiritigenin suppresses the activation of hepatic stellate cells via targeting miR-181b/PTEN axis
- Bilingual Status
- semi_complete